Scancell books loss as it develops cancer treatments, Covid-19 vaccine
Immunotherapies producer Scancell booked a full-year loss as it continued to incur development costs fortreatment and vaccine candidates, including for cancer and Covid-19.
Pre-tax losses...
Fri, 16/10/2020 - 07:32